LARIMAR THERAPEUTICS, INC. (LRMR) Debt Components
- 2020-03-31: Notes Payable, CurrentUSD $7.27M; Long-term Line of CreditUSD (m); Notes PayableUSD $12.73M; Long-term DebtUSD (m).
- 2019-12-31: Notes Payable, CurrentUSD $7.27M; Long-term Line of CreditUSD (m); Notes PayableUSD $14.54M; Long-term DebtUSD (m).
- 2019-12-31: Notes Payable, CurrentUSD (m); Long-term Line of CreditUSD (m); Notes PayableUSD (m); Long-term DebtUSD $14.54M.
- 2019-09-30: Notes Payable, CurrentUSD $7.27M; Long-term Line of CreditUSD (m); Notes PayableUSD $16.36M; Long-term DebtUSD $16.36M.
LARIMAR THERAPEUTICS, INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Long-term Line of Credit USD | Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Line of Credit Facility, Average Outstanding Amount USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Line of Credit Facility, Interest Rate During Period pure | Line of Credit Facility, Periodic Payment, Interest USD | Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid USD | Debt Instrument, Unamortized Discount USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2020-03-31 | $7.27M | (m) | $12.73M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.29M | (m) |
| 2019-12-31 | $7.27M | (m) | $14.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $1.19M | (m) |
| 2019-12-31 | (m) | (m) | (m) | $14.54M | $7.27M | $7.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $7.27M | (m) | $16.36M | $16.36M | (m) | $7.27M | $7.27M | (m) | $1.82M | (m) | (m) | (m) | (m) | $1.07M | (m) |
| 2019-06-30 | $7.27M | (m) | $18.18M | $18.18M | (m) | $7.27M | $7.27M | (m) | $3.64M | (m) | (m) | (m) | (m) | $945.00K | (m) |
| 2019-03-31 | $7.27M | (m) | $20.00M | $20.00M | (m) | $7.27M | $7.27M | (m) | $5.46M | (m) | (m) | (m) | (m) | $799.00K | (m) |
| 2018-12-31 | $5.46M | (m) | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $640.00K | (m) |
| 2018-12-31 | (m) | (m) | (m) | $20.00M | $5.46M | $7.27M | $7.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $3.64M | (m) | $20.50M | $20.00M | (m) | $5.45M | $7.27M | $7.27M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $1.82M | (m) | $20.30M | $20.00M | (m) | $5.45M | $7.27M | $7.27M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $20.20M | $20.00M | (m) | $5.45M | $7.27M | $7.27M | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | $20.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | $0.00 | $5.45M | $7.27M | $7.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $1.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $2.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $2.84M | (m) | $2.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $3.59M | (m) | $3.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 8.10% | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | $3.18M | $3.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $3.12M | (m) | $3.94M | $3.94M | (m) | $3.18M | (m) | (m) | $756.00K | (m) | (m) | (m) | (m) | $394.00K | $14.00K |
| 2016-06-30 | $3.06M | (m) | $4.68M | $4.68M | (m) | $3.18M | (m) | (m) | $1.50M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $3.00M | (m) | $5.41M | $5.41M | (m) | $3.18M | (m) | (m) | $2.22M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $2.94M | (m) | $6.12M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $306.00K | $36.00K |
| 2015-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 8.10% | (m) | (m) | (m) |
| 2015-09-30 | $2.88M | (m) | $6.82M | $6.82M | (m) | $2.94M | $3.18M | (m) | $697.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $426.00K | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $213.00K | (m) | (m) |
| 2015-06-30 | $2.82M | (m) | $7.50M | $7.50M | (m) | $2.94M | $3.18M | (m) | $1.38M | (m) | (m) | (m) | (m) | $227.00K | $56.00K |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $213.00K | (m) | (m) |
| 2015-03-31 | $2.09M | (m) | $7.50M | $7.50M | (m) | $2.94M | $3.18M | (m) | $1.38M | (m) | (m) | (m) | (m) | $181.00K | $67.00K |
| 2014-12-31 | $1.38M | (m) | $7.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $137.00K | $79.00K |
| 2014-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 8.10% | 12 month · $870.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $658.00K | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $213.00K | (m) | (m) |
| 2014-09-30 | $684.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $445.00K | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $443.00K | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $20.00M | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $2.00K | (m) | (m) |
| 2013-12-31 | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |